Company news

The IMM0306 project of ImmuneOnco was accepted by FDA for clinical trial

Date:2020-12-10 Views:750

On December 10, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (Project No.: IMM0306) independently developed by the company and targeting CD47 and CD20 simultaneously has obtained the application(Application Type/Number: IND151570). This is the first project to submit IND application to FDA of the United States in addition to a number of clinical trial research projects carried out in China. It marks that in addition to the clinical trial research in China, the company has officially arranged to carry out clinical trial research in the United States, which is a major strategic layout and a major milestone event of the company's development.

"I am very glad to see that our IMM0306 project has successfully submitted FDA clinical trial research application, which marks the recognition and expectation of our independent innovation project in the world's top markets like the United States. IMM0306 is an antibody receptor recombinant protein (mAb-Trap) targeting both CD47 and CD20. It is the first CD47xCD20 double target specific molecule in the world. IMM0306 does not combine with human red blood cells, and its efficacy is significantly better than that of Rituximab at the same dose. It is hopeful that IMM0306 will replace Rituximab as the first-line treatment option for patients with B-cell lymphoma in the future. At present, the phase I clinical trial of the project is progressing smoothly in China, and we are looking forward to the future of IMM0306. " Dr. Tian Wenzhi, founder of ImmuneOnco, is confident in the clinical trial of IMM0306, "we will continue to further expand the clinical trial research of IMM0306 project, so as to benefit more subjects. At the same time, we will accelerate the pace of IMM0306 launch to benefit cancer patients as soon as possible. ".

About IMM0306

IMM0306 is an antibody receptor recombinant protein (mAb-Trap) targeting CD47 and CD20 simultaneously. It is the world's first (First-In-Class) bispecific antibody drug with independent intellectual property rights of ImmuneOnco. The drug can act on tumor disease targets and regulate immune system at the same time, and play a strong anti-tumor effect by activating macrophages and NK cells.

About ImmuneOnco

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, and TANKTM cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.

Contact us

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

             Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573